ITMN-520

ITMN-520 is a small molecule pirfenidone analog that was developed by InterMune for the treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic conditions. As a next-generation compound in InterMune's pulmonology portfolio, it was designed to improve upon the efficacy or safety profile of pirfenidone (Esbriet). Like its parent compound, ITMN-520 is thought to possess anti-fibrotic and anti-inflammatory properties, potentially through the modulation of transforming growth factor-beta (TGF-beta) and tumor necrosis factor-alpha (TNF-alpha) pathways. Development of the compound appears to have been discontinued or deprioritized following the regulatory success of pirfenidone and the subsequent acquisition of InterMune by Roche in 2014.